Vivtex Partners with Equillium to Develop EQ302 for Gastrointestinal Inflammation
Shots:
- Vivtex and Equillium have signed a research and licensing agreement for the development of EQ302 to treat GI inflammation. Financial terms were undisclosed
- The partnership will leverage Vivtex’s AI-based GI-ORIS screening & formulation platform to develop EQ302’s oral formulation for GI inflammation. Equillium gets licensing option in return of royalties and other payments
- EQ302 is a bi-specific inhibitor of IL-15 and IL-21. Its optimized oral formulation is expected to offer robust anti-inflammatory effects with greater convenience compared to current biologics. P-I study is planned during H1’25
Ref: Globenewswire | Image: Vivtex & Equillium
Related News: Equillium Entered into an Exclusive Option and Asset Purchase Agreement with Ono to Develop and Commercialize Itolizumab
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
